Abstract:The use of existing mouse models in cancer research is of utmost importance as they aim to explore the casual link between candidate cancer genes and carcinogenesis as well as to provide models to develop and test new therapies. However, faster progress in translating mouse cancer model research into the clinic has been hampered due to the limitations of these models to better reflect the complexities of human tumors. Traditionally, immunocompetent and immunodeficient mice with syngeneic and xenografted tumors transplanted subcutaneously or orthotopically have been used. These models are still being widely employed for many different types of studies, in part due to their widespread availability and low cost. Other types of mouse models used in cancer research comprise transgenic mice in which oncogenes can be constitutively or conditionally expressed and tumor-suppressor genes silenced using conventional methods, such as retroviral infection, microinjection of DNA constructs, and the so-called "gene-targeted transgene" approach. These traditional transgenic models have been very important in studies of carcinogenesis and tumor pathogenesis, as well as in studies evaluating the development of resistance to therapy. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing approach has revolutionized the field of mouse cancer models and has had a profound and rapid impact on the development of more effective systems to study human cancers. The CRISPR/Cas9-based transgenic models have the capacity to engineer a wide spectrum of mutations found in human cancers and provide solutions to problems that were previously unsolvable. Recently, humanized mouse xenograft models that accept patient-derived xenografts and CD34+ cells were developed to better mimic tumor heterogeneity, the tumor microenvironment, and cross-talk between the tumor and stromal/immune cells. These features make them extremely valuable models for the evaluation of investigational cancer therapies, specifically new immunotherapies. Taken together, improvements in both the CRISPR/Cas9 system producing more valid mouse models and in the humanized mouse xenograft models resembling complex interactions between the tumor and its environment might represent one of the successful pathways to precise individualized cancer therapy, leading to improved cancer patient survival and quality of life.

Transgenic Mouse Models in the Study of Ovarian Function

Genetically modified mouse models addressing gonadotropin function

Studying the Functions of TGF-β Signaling in the Ovary.

A Mouse Model Reveals the Events and Underlying Regulatory Signals During the Gonadotrophin-Dependent Phase of Follicle Development

Relevance, strategies, and added value of mouse models in androgenetics

Oogenesis: Transcriptional regulators and mouse models

A spatiotemporal molecular atlas of the ovulating mouse ovary

Production of Transgenic Mice by Random Recombination of Targeted Genes in Female Germline Stem Cells.

Oocyte-derived Microvilli Control Female Fertility by Optimizing Ovarian Follicle Selection in Mice

Emerging and Evolving Ovarian Cancer Animal Models

Uterine Disorders and Pregnancy Complications: Insights from Mouse Models.

Transgenic mice applications in the study of endometriosis pathogenesis

Transgenic Mouse Models in Cancer Research

Mouse Models for Multistep Tumorigenesis

A Time-Resolved Transcriptome Landscape of the Developing Mouse Ovary

Infertility Caused By Retardation Of Follicular Development In Mice With Oocyte-Specific Expression Of Foxo3a

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

Thirteen Ovary-Enriched Genes Are Individually Not Essential for Female Fertility in Mice

Somatic Genome-Engineered Mouse Models Using In Vivo Microinjection and Electroporation

Knockout mouse models and mammary tumorigenesis.

Mouse Models of BRCA1 and Their Application to Breast Cancer Research